"Over 300 million dollars!"
Recently, Yao Tang Bio, a new area company, announced that itachieve more thanRMB 300 million Series B financing. This round of financing was led by AstraZeneca Zhongjin Medical Industry Fund and followed by a number of well-known investment institutions. By now, the company's cumulative financing has exceeded RMB 575 million.
Not only Yao Tang Bio
On the track of gene and cell therapy
Recently, a number of other businesses in the new district
ushering in new progress and breakthroughs
Good news all the time.
01 300 million financing "attraction" full of power
Walking into the GMP production base of Yaotang Bio, the staff is busy, one piece of clinical drugs will be shipped to all over the world after going through strict procedures such as inspection and packaging.
These clinical drugs are Yao Tang Bio's innovative in vivo gene editing drugs. If we imagine human genes as an encyclopedia, in vivo gene editing is the process of finding a precise letter (disease-causing gene) in the encyclopedia and editing it. Especially for hereditary diseases, it can "treat both the symptoms and the root cause".
In this highly technological track, there are currently no more than 10 companies worldwide conducting in vivo gene editing drug development. Among them.Yao Tang Bio is the first company in China and also the company with the most clinical pipelines in the world, with four in vivo gene editing drug pipelines "running into" the clinical stage.The
"Our self-developed YOLT-101 is the first in vivo base editing therapy in China that has been approved for clinical trial applications in both China and the United States." Dr. Wu Yuxuan, founder of Yao Tang Bio, introduced the drug for the treatment of familial hypercholesterolemia. Familial hypercholesterolemia. Current medications for hyperlipidemia require patients to take them year-round, while YOLT-101Potential to achieve "once-dosed, lifelong lipid lowering", which will bring a new treatment paradigm to patients, is expected to be available in about 3 years.
The company has written new answers for once "unsolved" diseases. Such innovative strength and clinical transformation speed, also transformed into not bad "attracting power" - more than 300 million yuan of B round of financing, is recognized from all sides, but also the enterprise fast running forward thrust.
"We will continue to be original-driven and focus on translating the world's leading in vivo gene editing technology into truly innovative drugs that can be used in the treatment of diseases, bringing breakthrough changes to more patients." Wu Yuxuan said.
02 Stronger together "group" to go to sea
Gene therapy companies have won financing, and on the other side, there are new stories written in the cell therapy track: recently, Reindeer Bio and Saiqiao Bio signed a global strategic cooperation agreement, which will jointly promote the integration of domestic advanced cell therapy drug industry chain to go overseas.
As a leading company in the field of cell therapy, Reindeer Biologics launched Fukosu, which is China's first CAR-T product that is completely independently researched and developed and independently produced in the whole process, and has benefited hundreds of multiple myeloma patients in more than 10 countries and regions since it was listed on the market. In order to benefit more patients around the world as soon as possible, the team has been exploring new modes of drug exporting to the sea, and so far this year, it has taken the first overseas marketing license in Macau, China.
In addition to promoting the approval of products in more countries and regions, how else can domestic CAR-T innovative drugs be "exported"?
The "strong alliance" between Reindeer Bio and Saiqiao Bio is a new path of cooperation.According to the introduction, Saiqiao Bio is the earliest enterprise in China that is deeply engaged in cell processing and automation equipment, and its high-end equipment can promote the cell preparation from the traditional handmade mode to the intelligent upgrading; similarly, Reindeer Bio has accumulated profound experience in drug research and development for many years.
On this basis.The two companies will work together to establish a process development mechanism to enhance the production of cell therapy products."Feasibility".In addition, the two sides will integrate each other's international channel resources to promote the landing and application of the overall solution in overseas markets.
The two upstream and downstream enterprises to work together, not only is the complementary resources, but also technology, technology and services of the "group to the sea". When the production is faster and the cost is lower, the domestic cell therapy drugs, but also to a broader stage.
There are many new developments worth mentioning, not just financing and going overseas:
Shiho One® Pan-Solid Tumor High-Throughput Sequencing Genetic Test Kit, independently developed by Shiho Genetics, has become the world's first and only tumor high-throughput sequencing panel test product that has been certified by three international authoritative regulatory agencies, namely, NMPA, FDA, and CE, and has won the "Grand Slam".
Beiheng Bio's Generic CAR-T Product CTD402 Receives FDA Pediatric Rare Disease Designation for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma ......
One by one, the good news comes, behind is the fast pace of the enterprise, but also the industrial layout of the innovation brought about by the surge.new areaBiomedical Valley, which hasassembleMore than 40 cell and gene technology innovatorsIt has formed a whole industrial chain from gene testing and reagents to mouse gene editing, CAR-T cell therapy and targeted drugs, and a number of global and national leading products and technologies have emerged and gone global since then.
The future deserves more.
